Literature DB >> 16790263

Treatment and prognosis of post term choriocarcinoma in The Netherlands.

Christianne A Lok1, Anca C Ansink, Danielle Grootfaam, Jacobus van der Velden, Rene H Verheijen, Marianne J ten Kate-Booij.   

Abstract

INTRODUCTION: Antecedent term pregnancy is an adverse prognostic factor in Gestational Trophoblastic Disease (GTD). In The Netherlands, patients with post term choriocarcinoma are considered high-risk independent of WHO score. In the present study, we assessed whether post term choriocarcinoma always has to be considered high-risk, requiring first line treatment with combination chemotherapy, or whether a subgroup of patients is distinguishable in which single-agent Methotrexate is a safe alternative. PATIENTS AND METHODS: The study is a retrospective multicenter cohort study. Patients registered by the Dutch Working Party on Trophoblastic Disease between 1986 and 2004 with choriocarcinoma after a non-molar pregnancy were eligible. Hospital and outpatient records of the patients were reviewed.
RESULTS: In total, 68 patients with non-molar choriocarcinoma were registered of whom 44 had an antecedent term pregnancy. Most post term patients (77%) were high-risk according to the WHO staging system. The majority of patients presented with metrorraghia and high hCG levels. Lung and liver metastases were common (respectively 64% and 28%), probably caused by a delay in diagnosis (median interval 16 weeks). Patients were often Methotrexate-resistant (75%). Overall survival was 86% in patients with a post term choriocarcinoma.
CONCLUSIONS: Although term pregnancy is an adverse prognostic factor in GTD, current survival is comparable to the general survival in high-risk patients. A subgroup of patients in which monotherapy would be sufficient could not be identified. Immediate administration of combination chemotherapy seems justified, even in those few cases when scoring systems would suggest low- or medium-risk disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16790263     DOI: 10.1016/j.ygyno.2006.05.011

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

1.  Gestational trophoblastic neoplasia: treatment outcomes from a single institutional experience.

Authors:  H Al-Husaini; H Soudy; A Darwish; M Ahmed; A Eltigani; W Edesa; T Elhassan; A Omar; W Elghamry; H Al-Hashem; S Al-Hayli; I Madkhali; S Ahmad; I A Al-Badawi
Journal:  Clin Transl Oncol       Date:  2014-11-15       Impact factor: 3.405

2.  In vitro evaluation of combination of EGCG and Erlotinib with classical chemotherapeutics on JAR cells.

Authors:  Elçin Telli; Hatice Genç; Burcugül Altuğ Tasa; S Sinan Özalp; A Tansu Koparal
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-05-01       Impact factor: 2.416

3.  Clinical characteristics and prognosis of 272 postterm choriocarcinoma patients at Peking Union Medical College Hospital: a retrospective cohort study.

Authors:  Jie Li; Junjun Yang; Pengfei Liu; Tong Ren; Jun Zhao; Fengzhi Feng; Xirun Wan; Yang Xiang
Journal:  BMC Cancer       Date:  2016-06-02       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.